Global Dental Surgical Equipment Market Expands on Rising Oral Disease Burden According to a newly published market research report by 24LifeSciences, global dental surgical equipment market was valued at USD 5,808 million in 2024 and is projected to reach USD 7,727 million by 2031, growing at a compound annual growth rate (CAGR) of 4.3% during the forecast period 2025-2031. Dental surgical equipment comprises the specialized instruments and devices used for the diagnosis, surgical intervention, and treatment of oral diseases and conditions. This includes a wide array of products from diagnostic imaging systems and lasers to therapeutic instruments, delivery systems, and surgical handpieces. These tools are essential for procedures ranging from routine tooth extractions to complex dental implantology and maxillofacial surgeries, forming the backbone of modern oral healthcare delivery. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9104/dental-surgical-equipment-market

What Is the Future of the Dental Electrosurgical Generators Market? Growth Insights According to a newly published market research report by 24LifeSciences, global dental surgery electrosurgical generators market was valued at USD 285 million in 2024 and is projected to reach USD 425 million by 2032, growing at a compound annual growth rate (CAGR) of 5.1% during the forecast period. Dental surgery electrosurgical generators are advanced medical devices that produce high-frequency electrical currents for cutting, coagulating, desiccating, and fulgurating tissues during dental procedures. These systems are indispensable in modern dentistry, enabling precise soft tissue management with minimized bleeding and enhanced surgical visibility. Available in monopolar and bipolar configurations, they are essential tools for procedures ranging from gingivectomies to implantology, supporting both routine and complex oral surgeries. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/10136/dental-surgery-electrosurgical-generators-market

Tissue Sealants and Adhesives Market to Reach USD 7.26 Billion by 2032 | Trends & Forecast According to a newly published market research report by 24LifeSciences, global tissue sealants and tissue adhesive market was valued at USD 4.12 billion in 2024 and is projected to reach USD 7.26 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.4% during the forecast period 2025–2032. Tissue sealants and adhesives are advanced biomaterials used to achieve hemostasis and approximate wound edges, effectively replacing or supplementing traditional sutures and staples. These products function by creating a barrier or bond that promotes natural healing while preventing fluid or air leakage from tissues and organs. Major product categories include fibrin sealants, collagen-based sealants, synthetic adhesives like cyanoacrylates, and albumin-based glues, each designed for specific surgical applications across cardiovascular, orthopedic, and general surgery. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/10358/tissue-sealants-and-tissue-adhesive-market

FibroTouch Devices Market Size to Reach USD 220 Million by 2032 | Growth Insights Global FibroTouch Devices market is undergoing steady expansion as healthcare systems increasingly prioritize non-invasive diagnostics for liver disease management. Valued at USD 120 million in 2024, the market is projected to grow from USD 132 million in 2025 to USD 220 million by 2032, registering a CAGR of 7.8% during the forecast period. This growth reflects a structural shift away from invasive liver biopsies toward faster, safer, and more patient-friendly elastography-based solutions that deliver real-time clinical insights. The FibroTouch Devices market is gaining prominence across hospitals, diagnostic centers, and specialty clinics as chronic liver conditions such as NAFLD, viral hepatitis, and alcoholic liver disease continue to rise globally. Increasing disease awareness, early screening initiatives, and technological refinements are positioning FibroTouch as a core diagnostic modality in modern hepatology workflows. Access the market report https://www.24lifesciences.com/fibrotouch-devices-market-9969

Tardive Dyskinesia Treatment Market Size to Reach USD 1.3 Billion by 2032 | Growth Insights Global Tardive Dyskinesia Treatment market is undergoing a notable transformation as healthcare systems prioritize early diagnosis, neurological specialization, and precision pharmacotherapy. Valued at USD 643.5 million in 2024, the market is projected to grow from USD 720.6 million in 2025 to USD 1.3 billion by 2032, expanding at a CAGR of 9.2% during the forecast period. Rising awareness of movement disorders, increased use of long-term antipsychotic therapies, and the growing adoption of FDA-approved VMAT2 inhibitors are central to this sustained growth trajectory. Access the market report https://www.24lifesciences.com/tardive-dyskinesia-treatment-market-10341

Dental CBCT Scan Market Size to Reach USD 1.96 Billion by 2032 | Growth Insights & Forecasts Global Dental CBCT scan market is undergoing sustained expansion as dentistry rapidly transitions toward precision-driven, digital diagnostic workflows. Valued at USD 1.14 billion in 2024, the market is projected to grow from USD 1.24 billion in 2025 to reach USD 1.96 billion by 2032, registering a CAGR of 6.7% over the forecast period. Increasing demand for implantology, orthodontics, and minimally invasive oral surgery is positioning CBCT technology as a cornerstone of modern dental diagnostics. Access the market report https://www.24lifesciences.com/dental-cbct-scan-market-9779

What Is the Future of the Tyrosine Hydroxylase Deficiency Drugs Market? Growth Forecasts & Insights Global Tyrosine Hydroxylase Deficiency Drugs market is gaining strategic importance within the rare neurological disorders landscape, supported by advancing diagnostics and heightened clinical awareness. Valued at USD 12.5 million in 2024, the market is projected to grow from USD 13.8 million in 2025 to USD 22.1 million by 2032, registering a CAGR of 6.9% during the forecast period. This sustained growth reflects increasing recognition of Tyrosine Hydroxylase Deficiency (THD) as a treatable condition requiring lifelong, specialized therapeutic management. Access the market report https://www.24lifesciences.com/tyrosine-hydroxylase-deficiency-drugs-market-9215

Patient Derived Xenograft (PDX) Models Market Size to Reach USD 653 Million by 2032 Global Patient Derived Xenograft (PDX) Models market is witnessing strong momentum as precision oncology and personalized medicine reshape cancer drug development worldwide. Valued at USD 358 million in 2024, the market is projected to reach USD 653 million by 2032, expanding at a robust CAGR of 9.2% during the forecast period. Increasing demand for highly predictive preclinical models, coupled with rising oncology R&D investment, continues to position PDX models as a cornerstone of modern translational cancer research. Access the market report https://www.24lifesciences.com/patient-derived-xenograft-pdx-models-market-9495

Mendelian Disorders Testing Market Size to Reach USD 7.8 Billion by 2032 | Growth Trends & Insights Global Mendelian disorders testing market is gaining strong momentum as healthcare systems worldwide intensify their focus on early diagnosis, preventive screening, and precision medicine. The market is projected to expand from USD 4.6 billion in 2025 to USD 7.8 billion by 2032, registering a robust compound annual growth rate (CAGR) of 7.8% during the forecast period. This sustained growth reflects rising awareness of inherited diseases, expanding newborn and prenatal screening programs, and rapid advancements in genomic testing technologies. Access the market report https://www.24lifesciences.com/mendelian-disorders-testing-market-9526

Oral Thrush Market Size to Reach USD 8.52 Billion by 2032 | Growth Trends & Forecasts Global Oral Thrush market continues to demonstrate steady expansion, supported by rising awareness of fungal infections, improved access to antifungal therapies, and increasing prevalence of immunocompromising conditions worldwide. Valued at USD 7.11 billion in 2024, the market is projected to grow from USD 7.29 billion in 2025 to USD 8.52 billion by 2032, registering a CAGR of 2.7% over the forecast period. Sustained demand from vulnerable populations and consistent treatment needs underpin the market’s long-term stability. Access the market report https://www.24lifesciences.com/oral-thrush-market-9566